2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Metabolism, Clinical Practice (Health Services and Quality), Patient Safety, Quality of Care, Diseases, Lymphoid Malignancies, Lymphomas, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

1891 Rocbrutinib plus R-CHOP in previously untreated non-GCB diffuse large B-cell lymphoma: Updated safety and efficacy Results from a Phase Ib study

Qingqing Cai, MD, Yi Xia2, Huangming Hong3, Junfeng Jiang4, Xiaojie Fang5, Huang He6, Zhongjun Xia, MD, PhD7, Man Nie8, Bing BAI, MD9, Shenrui Bai10, Zheng Wang11, Mingyu Jia12, Yejiang Lou, MD, PhD13, Yue Shen, PhD14, Fenlai Tan15
1 Sun Yat-sen University Cancer Center, Guangzhou, China
2 Sun Yat-sen University Cancer Center, Guangzhou, China
3 Sichuan Cancer Hospital, Chengdu, China
4 Gansu Provincial Cancer Hospital, Lanzhou, China
5 Sun Yat-sen University Cancer Center, Guangzhou, China
6 Sun Yat-sen University Cancer Center, Guangzhou, China
7 Sun Yat-sen University Cancer Center, Guangzhou, China
8 Sun Yat-sen University Cancer Center, Guangzhou, China
9 Sun Yat-sen University Cancer Center, Guangzhou, China
10 Sun Yat-sen University Cancer Center, Guangzhou, China
11 Guangzhou Lupeng Pharmaceutical Co., Ltd., Guangzhou, Guangdong, China
12 Guangzhou Lupeng Pharmaceutical Co., Ltd., Guangzhou, Guangdong, China
13 Guangzhou Lupeng Pharmaceutical Co., Ltd., Guangzhou, Guangdong, China
14 Guangzhou Lupeng Pharmaceutical Co., Ltd., Guangzhou, Guangdong, China
15 Guangzhou Lupeng Pharmaceutical Co., Ltd., Guangzhou, Guangdong, China

Introduction: Patients with non-germinal center B-cell (non-GCB) diffuse large B-cell lymphoma (DLBCL) remain at increased risk of relapse or refractory disease following standard frontline immunochemotherapy, highlighting the need for improved frontline treatment strategies. Rocbrutinib is a novel fourth-generation BTK inhibitor designed to enable both covalent and non-covalent binding depending on whether BTK was wide type or C481 mutant variant. Preliminary findings from this ongoing phase Ib study demonstrated encouraging clinical activity and a manageable safety profile (ESMO 2026, 1457O). Here, we report updated safety and efficacy results with extended follow-up, including outcomes in participants with double-expressor DLBCL.

Methods: This is an ongoing, open-label, multicenter, phase Ib study comprised of dose-escalation and dose-expansion parts (NCT06251180). Participants with previously untreated B-cell lymphoma received rocbrutinib once daily at 100 mg (dose level 1 [DL1]), 150 mg (DL2), or 200 mg (DL3) in combination with standard R-CHOP for six 21-day cycles, followed by rocbrutinib plus rituximab for two additional 21-day cycles, and subsequently rocbrutinib monotherapy maintenance for up to twenty-four 28-day cycles. Primary endpoints were safety and pharmacokinetics. Secondary endpoints included investigator-assessed overall response rate (ORR), complete response (CR) rate, progression-free survival (PFS), and overall survival (OS) per Lugano 2014 criteria.

Results: As of June 24, 2026, 29 participants had been enrolled (DL1, n = 4; DL2, n = 15; DL3, n = 10), with a median age of 58 years (range, 38–69), and 58.6% were male. Efficacy analyses were performed in the 27 participants with non-GCB DLBCL, among whom 74.1% had stage III–IV disease (51.9% stage IV), 77.8% had extranodal involvement, 29.6% had an International Prognostic Index (IPI) score of 3–5, 29.6% had double-expressor lymphoma, and 18.5% had bulky disease (≥7.5 cm).

No dose-limiting toxicities were observed. Treatment-related adverse events (TRAEs) occurred in all participants. The most common TRAEs were hematologic toxicities, including neutropenia (93.1%; grade ≥3, 75.9%), leukopenia (93.1%; grade ≥3, 75.9%), thrombocytopenia (82.8%; grade ≥3, 13.8%), and anemia (79.3%; grade ≥3, 10.3%). The most common grade ≥3 non-hematologic TRAEs were pneumonia (20.7%) and febrile neutropenia (10.3%). No atrial fibrillation or major bleeding was reported. Dose reductions of rocbrutinib due to TRAEs occurred in 2 participants (6.9%); no treatment discontinuations or deaths related to TRAEs were reported.

Among 26 efficacy-evaluable participants with DLBCL who completed ≥4 treatment cycles, the ORR was 100.0% (26/26), including a CR rate of 92.3% (24/26). Among participants with CR who underwent circulating tumor DNA (ctDNA)-based measurable residual disease (MRD) assessment, 92.3% (12/13) achieved MRD negativity. Encouraging clinical activity was also observed in participants with double-expressor DLBCL (n = 8), with an ORR of 100.0% (8/8), a CR rate of 87.5% (7/8), and all evaluable participants (5/5) achieved MRD negativity.

With a median follow-up of 8.5 months (range, 0.8–23.2), median PFS and OS were not reached. At the data cutoff, only one participant (3.7%) had experienced disease progression.

Conclusions: Rocbrutinib plus R-CHOP demonstrated a manageable safety profile and encouraging clinical activity in previously untreated non-GCB DLBCL, with high complete response rate and ctDNA-based MRD negativity rate. These updated findings support continued clinical evaluation of this regimen in frontline non-GCB DLBCL.
Qingqing Cai, MD: No relevant conflicts of interest to declare.